Erratum: Objective assessment of tumour response to therapy based on tumour growth kinetics (British Journal of Cancer (2011) 105 (682-686) DOI: 10.1038/bjc.2011.276);Objective assessment of tumour response to therapy based on tumour growth kinetics

British Journal of Cancer

Volumn 105, Issue 5, 2011, Pages 682-686

  Mehrara, E ^a   Forssell Aronsson, E ^a   Bernhardt, P ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cytostatic; cytotoxic; growth kinetics; response; therapy; tumour

Indexed keywords

ANTIBODY; CYTOSTATIC AGENT; CYTOTOXIC AGENT; IODINE 131; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DATA ANALYSIS; DIET SUPPLEMENTATION; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; ISOTOPE LABELING; KINETICS; MATHEMATICAL ANALYSIS; NONHODGKIN LYMPHOMA; ONCOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

EID: 80052025455     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.436     Document Type: Erratum

References (31)

1. Barnacle AM, McHugh K (2006) Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatr Blood Cancer 46(2): 127-134 (Pubitemid 43076061)
2. Blankenberg FG, Teplitz RL, Ellis W, Salamat MS, Min BH, Hall L, Boothroyd DB, Johnstone IM, Enzmann DR (1995) The influence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas. Am J Neuroradiol 16(5): 1001-1012
3. Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH (2008) Application of PET/CT in the development of novel anticancer drugs. Oncologist 13(1): 25-38 (Pubitemid 351206694)
4. Chenevert TL, McKeever PE, Ross BD (1997) Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3(9): 1457-1466 (Pubitemid 27431551)
5. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5): 579-586 (Pubitemid 350002966)
6. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13): 1753-1759 (Pubitemid 46797957)
7. Cucchetti A, Vivarelli M, Piscaglia F, Nardo B, Montalti R, Grazi GL, Ravaioli M, La Barba G, Cavallari A, Bolondi L, Pinna AD (2005) Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 43(2): 310-316 (Pubitemid 40956885)
8. Davis AJ, Tannock JF (2000) Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 1: 86-93
9. Duhaylongsod FG, Lowe VJ, Patz Jr EF, Vaughn AL, Coleman RE, Wolfe WG (1995) Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60(5): 1348-1352
10. Eisenhauer EA (2007) Response evaluation: beyond RECIST. Ann Oncol 18(Suppl 9): ix29-ix32
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247
12. Guess B, Jennrich R, Johnson H, Redheffer R, Scholz M (2003) Using splines to detect changes in PSA doubling times. Prostate 54(2): 88-94 (Pubitemid 36120324)
13. Gwyther SJ, Schwartz LH (2008) How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer 44(1): 39-45 (Pubitemid 350256945)
14. Haney SM, Thompson PM, Cloughesy TF, Alger JR, Frew AJ, Torres-Trejo A, Mazziotta JC, Toga AW (2001) Mapping therapeutic response in a patient with malignant glioma. J Comput Assist Tomogr 25(4): 529-536 (Pubitemid 33041508)
15. Jaffe CC (2008) Response assessment in clinical trials: implications for sarcoma clinical trial design. Oncologist 13(Suppl 2): 14-18
16. Karrison TG, Maitland ML, Stadler WM, Ratain MJ (2007) Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99(19): 1455-1461
17. Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5(7): 516-525 (Pubitemid 40942828)
18. Lavin PT (1981) An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 4(4): 451-457
19. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P (2007) Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 67(8): 3970-3975 (Pubitemid 46762187)
20. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P (2009) Quantitative analysis of tumor growth rate and changes in tumor marker level: specific growth rate versus doubling time. Acta Oncol 48(4): 591-597
21. Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6(5): 409-414
22. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1): 207-214 (Pubitemid 11167383)
23. Padhani AR, Miles KA (2010) Multiparametric imaging of tumor response to therapy. Radiology 256(2): 348-364
24. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7): 1148-1159
25. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD (2003) Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med 44(2): 260-268
26. Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T (2008) Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 13(10): 1046-1054
27. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39(14): 2012-2020 (Pubitemid 37297757)
28. Tann M, Sandrasegaran K, Winer-Muram HT, Jennings SG, Welling ME, Fletcher JW (2008) Can FDG-PET be used to predict growth of stage I lung cancer? Clin Radiol 63(8): 856-863
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216 (Pubitemid 30099779)
30. Tuma RS (2006) Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 98(18): 1272-1274
31. Twombly R (2006) Criticism of tumor response criteria raises trial design questions. J Natl Cancer Inst 98(4): 232-234